teRule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, o1/o9/99, o1/o7/00, 30/09/01, 11/03/02, o1/o1/03, 24/10/05, o1/o8/12, o4/o3/13$

HERC	ON RESOURCES LIMITED	
ABN		
30 068	3 263 098	
We (t	he entity) give ASX the followin	g information.
	1 - All issues ust complete the relevant sections (attack	ch sheets if there is not enough space).
1	⁺ Class of ⁺ securities issued or to be issued	Convertible Notes
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	34,995,220 Convertible Notes
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Convertible Notes with a maturity date of 31 December 2024 which are convertible into fully paid ordinary shares on the terms approved by shareholders on 5 December 2019.

Name of entity

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

 however, shares issued upon conversion of the Convertible Notes will rank equally in respects from the date of issue with existing fully paid ordinary shares.

5 Issue price or consideration

Convertible Notes issued with a face value of US\$1.00 each.

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

Part of a broader funding package to advance the Woodlawn Project to cash flow positive operations described in the ASX Announcement lodged with ASX on 4 October 2019.

Issued pursuant to shareholder approval received on 5 December 2019.

6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

No.

No

If Yes, complete sections 6b – 6h *in relation to the *securities the subject of this Appendix 3B*, and comply with section 6i

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	Nil
<i>(</i>)	Number of teconities issued	NT/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	34,995,220 Convertible Notes issued pursuant to shareholder approval received on 5 December 2019.
6f	Number of *securities issued under an exception in rule 7.2	Nil
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
	the VVVII carculation.	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer to Appendix 1.
	± 7 1 .	D 1
7	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	24 December 2019.

⁺ See chapter 19 for defined terms.

		Number	+Class
+	Number and ⁺ class of all ⁺ securities quoted on ASX (including the ⁺ securities in	418,664,605	Fully paid ordinary shares
	section 2 if applicable)	10,000,000	Fully paid ordinary shares subject to voluntary escrow until 15 October 2021
		Number	+Class
9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)	34,995,220	Convertible Notes with a maturity date of 31 December 2024 which are to be converted into fully paid ordinary shares on the terms approved by shareholders on 5 December 2019.
		1,085,000	Options exercisable at A\$0.72 and expiring 4 December 2020
		165,000	Options exercisable at A\$1.10 and expiring 1 February 2022
		1,860,000	Performance Rights vesting on 30 June 2020
		1,016,667	Performance Rights vesting on 30 June 2021
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	As per Company poshares.	olicy for all ordinary

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
	XA711 1 1 1 1 1 1 1 1 1 CC	
16	Will holdings on different registers (or subregisters) be aggregated for calculating	N/A
	entitlements?	
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who	N/A
	will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of	N/A
	acceptances or renunciations	

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	N/A

⁺ See chapter 19 for defined terms.

Part 3 - Quotation of securities You need only complete this section if you are applying for quotation of securities Type of *securities 34 (tick one) (a) +Securities described in Part 1 (b) All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible Entities that have ticked box 34(a) Additional securities forming a new class of securities Tick to indicate you are providing the information or documents If the +securities are +equity securities, the names of the 20 largest holders of 35 the additional +securities, and the number and percentage of additional *securities held by those holders If the +securities are +equity securities, a distribution schedule of the additional 36 *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over A copy of any trust deed for the additional *securities 37 Entities that have ticked box 34(b) Number of *securities for which 38 N/A ⁺quotation is sought ⁺Class of ⁺securities for which N/A 39 quotation is sought

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	N/A	N/A
			1

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Company secretary

Date: 24 December 2019

Print name: Simon Smith.....

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	241,666,912	
Add the following:	57,584,627	
Number of fully paid ⁺ ordinary securities issued in that 12 month period under an	67,808,109	
exception in rule 7.2	51,604,957	
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid +ordinary securities that became fully paid in that 12 month period		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	Nil	
"A"	418,664,605	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	62,799,690
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	10,000,000 Shares issued to Sedgman or 15 October 2019
• Under an exception in rule 7.2	
Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	10,000,000
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining
"A" x 0.15	62,799,690
Note: number must be same as shown in Step 2	
Subtract "C"	10,000,000
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	52,799,690
	[Note: this is the remaining placement capacity under rule 7.1]

⁺ See chapter 19 for defined terms.

Appendix 3B Page 12 04/03/2013

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	N/A	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	N/A	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	N/A	
Notes: • This applies to equity securities – not just ordinary securities • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained • It may be useful to set out issues of securities on different dates as separate line items		

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	N/A	
Note: number must be same as shown in Step 2		
Subtract "E"	N/A	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	N/A	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 14 04/03/2013

⁺ See chapter 19 for defined terms.